{
  "docId": "019de071-f0b8-737f-9ff6-e8b6f7a1e960",
  "docSlug": "213575480fcc7466657230c6a0d87626",
  "documentTitle": "23andMe | Investor Day Presentation Deck | 78 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 78,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "before_after",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a contrast-pairs framework to show the advantage of genetic evidence in drug development.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f0b8-737f-9ff6-e8b6f7a1e960/12",
  "deckHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960",
  "deckJsonHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960.json",
  "deckAnchorHref": "/decks/019de071-f0b8-737f-9ff6-e8b6f7a1e960#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "metric",
      "text": "7 years average time-to-IND",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8899b5e1-7f87-400f-b3ea-bcffe83ce2bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "metric",
      "text": "~90% failure rate",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf8e5fbf-4a6c-4e8a-900e-c9c41218a0e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.3,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "~4 years to IND with CD96 drug",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7adbca4b-0363-48a6-ab35-fd9b9dfdefd5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.3,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "Targets with genetic evidence have historically had a higher Success rate",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "80bceff6-548e-4de5-9332-88f642b0a792",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.96,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1 IND = Investigational New Drug Application... 2 Probability of success... 3 Nature Genetics Publication...",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3247766f-08d2-41b6-8b6f-a870a0ff69e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "source-note",
      "text": "NATURE GENETICS PUBLICATION: The support of human genetic evidence for approved drug indications, Nelson et. al 2015",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d5b7b25-0744-4f79-9c50-9eeb9249c088",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.55,
        "y": 0.2
      },
      "kind": "title",
      "text": "Potential to More Efficiently Develop Novel Therapeutics by \"Power, Need, and Speed\"",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "102fb1ba-c69a-4879-8997-cb777fd1997d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before/after framing",
      "slug": "before-after-framing",
      "agent": null,
      "layer": "slide",
      "matchId": "e2b6490d-5ee0-4271-b06c-ffb2dc642943",
      "evidence": "title/action-title: Potential to More Efficiently Develop Novel Therapeutics by \"Power, Need, and Speed\"",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "contrast-pairs",
      "slug": null,
      "matchId": "aebacfb5-3bee-4c3e-a9cd-683710c72a2d",
      "evidence": "Direct comparison of industry vs 23andMe metrics",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 12,
      "from": 11,
      "beatId": "157e8940-ed1d-49c6-a5d6-752e3012d12d",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "The presentation deck presents the limited use of genetic data and lack of patient engagement as constraints on productivity in therapeutics development",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 12,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "36b847ff-ac2b-4610-920d-b9252abc07a8",
      "evidence": "The presentation deck presents the limited use of genetic data and lack of patient engagement as constraints on productivity in therapeutics development",
      "position": 0,
      "objective": "What is the cost of not using genetic data and patient engagement in therapeutics development?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}